Lineage Cell Therapeutics (LCTX) Short-term Investments (2017 - 2026)

Lineage Cell Therapeutics has reported Short-term Investments for 10 years, with the latest figure at $17.4 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 91700.0% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $17.4 million (up 91700.0% YoY), and the FY2025 full-year result was $15.0 million, up 643.55% from the prior year.
• Short-term Investments for Q1 2026 stood at $17.4 million, up from $15.0 million in the prior quarter.
• The five-year high for Short-term Investments was $46.5 million in Q4 2022, with the low at $17000.0 in Q2 2025.
• Historically, Short-term Investments has averaged $11.3 million across 5 years, with a median of $5.0 million in 2024.
• Annual changes were most pronounced in 2023 — Short-term Investments plunged 99.89% — and 2026, when it surged 91700.0%.
• Lineage Cell Therapeutics' Short-term Investments stood at $46.5 million in 2022, then sank by 99.89% to $50000.0 in 2023, then jumped by 3932.0% to $2.0 million in 2024, then soared by 643.55% to $15.0 million in 2025, then gained by 16.36% to $17.4 million in 2026.
• The last three Short-term Investments figures came in at $17.4 million (Q1 2026), $15.0 million (Q4 2025), and $23000.0 (Q3 2025), per Business Quant data.